phrykt

Fulcrum Therapeutics, Inc. (FULC): who owns it and who trades it

As of Nov 16, 2026, FULC insiders reported 9 open-market sales worth $59.2M and 6 purchases worth $1.5M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was RA Capital Healthcare Fund LP (10% owner), with $58.4M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Fulcrum Therapeutics

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns FULC

155 funds and institutions reported FULC shares worth $316M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Nantahala Capital Management, LLC with 16.4%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Nantahala Capital Management, LLC16.4%
BlackRock, Inc.13.2%
EcoR1 Capital, LLC9.8%
Tang Capital Management LLC9.8%
Montanova Capital, LLC5.5%
D. E. Shaw & Co., Inc.4.6%
Citadel Advisors LLC4.1%
Vanguard Capital Management LLC4.0%
Jane Street Group, LLC3.3%
State Street Corp3.1%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Nantahala Capital Management, LLC10.95M16.43%$40.1M+259%
BlackRock, Inc.8.82M13.24%$32.3M+64%
EcoR1 Capital, LLC6.55M9.83%$24M–
Tang Capital Management LLC6.52M9.79%$23.9M–
Montanova Capital, LLC3.68M5.52%$13.5M-44%
D. E. Shaw & Co., Inc.3.04M4.57%$11.1M+88%
Citadel Advisors LLC2.70M4.06%$9.9M+109%
Vanguard Capital Management LLC2.70M4.05%$9.9M+0%
Jane Street Group, LLC2.22M3.33%$8.1M+614%
State Street Corp2.04M3.06%$7.5M+31%
Adage Capital Partners Gp, L.l.c.2.00M3.00%$7.3M+400%
GSK plc1.79M2.68%$6.5MNo change
Qube Research & Technologies Ltd1.75M2.62%$6.4M+79%
Assenagon Asset Management S.A.1.67M2.51%$6.1M+40%
Renaissance Technologies LLC1.65M2.47%$6M–
ADAR1 Capital Management, LLC1.57M2.35%$5.7M+1099%
Millennium Management LLC1.49M2.23%$5.4M+317%
Geode Capital Management, LLC1.43M2.15%$5.2M-4%
Marshall Wace, LLP1.36M2.04%$5M–
UBS Group AG1.25M1.88%$4.6M+298%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, FULC insiders reported $1.5M of open-market purchases and $59.2M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$1.5M
6 trades, 2 people
Sales, 12 months
$59.2M
9 trades, 4 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jul 17, 2026
Filed Jul 20, 2026

Purchases and sales by month

$58.4M$58.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 17, 2026Kevin Tang +110% ownerPurchase50,945$3.52$179KForm 4
Jul 16, 2026Kevin Tang +110% ownerPurchase116,671$3.56$415KForm 4
Jul 15, 2026Tang Capital Management Llc +110% ownerPurchase107,377$3.56$382KForm 4
Jul 14, 2026Tang Capital Management Llc +110% ownerPurchase75,952$3.58$272KForm 4
Jul 14, 2026Tang Capital Management Llc +110% ownerPurchase53,651$3.56$191KForm 4
Jul 13, 2026Tang Capital Management Llc +110% ownerPurchase12,966$3.54$45.9KForm 4
Jun 26, 2026Alan EzekowitzDirectorSale18,000$3.65$65.7KForm 4
Feb 2, 2026Robert J GouldDirectorSale15,000$10.72$161KForm 4
Jan 2, 2026Robert J GouldDirectorSale15,000$10.87$163KForm 4
Jan 2, 2026Robert J GouldDirectorSale15,000$11.87$178KForm 4
Dec 15, 2025Curtis Gale OltmansChief Legal OfficerSale3,452$12.92$44.6KForm 4
Dec 8, 2025RA Capital Healthcare Fund LP +310% ownerSale1.38M$13.33$18.4MForm 4
Dec 8, 2025RA Capital Healthcare Fund LP +310% ownerSale91,722$14.98$1.4MForm 4
Dec 8, 2025RA Capital Healthcare Fund LP +310% ownerSale2.71M$14.28$38.6MForm 4
Nov 19, 2025Robert J GouldDirectorSale15,000$11.03$165KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
RA Capital Healthcare Fund LP10% owner–$58.4MDec 8, 2025
Tang Capital Management Llc10% owner$891K–Jul 15, 2026
Robert J GouldDirector–$667KFeb 2, 2026
Kevin Tang10% owner$595K–Jul 17, 2026
Alan EzekowitzDirector–$65.7KJun 26, 2026
Curtis Gale OltmansChief Legal Officer–$44.6KDec 15, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

FULC short interest

Moderate short interest. 8.4% of FULC shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 17%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.44M FULC shares were sold short, 8.4% of the shares outstanding, down 4.7% from the report before. At the average daily volume of 1.34M shares, buying them all back would take about 4.8 trading days (days to cover).

Shares short, % of all shares

8.44%May 15Oct 3012.6%

Days to cover

4.8May 15Oct 3022.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.44M8.44%-5%1.34M4.8
Oct 15, 20266.76M8.86%-5%1.43M4.7
Sep 30, 20267.11M9.32%-1%1.59M4.5
Sep 15, 20267.19M9.43%+3%1.23M5.9
Aug 31, 20267.02M9.20%+5%2.07M3.4
Aug 14, 20266.66M8.72%+0%1.33M5.0
Jul 31, 20266.63M8.69%-4%1.46M4.5
Jul 15, 20266.91M10.37%+8%1.73M4.0
Jun 30, 20266.43M9.64%+16%4.33M1.5
Jun 15, 20265.52M8.29%-31%5.92M1.0
May 29, 20267.99M12.00%+2%403,60319.8
May 15, 20267.80M11.71%-2%574,21813.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Fulcrum Therapeutics company events

Fulcrum Therapeutics filed 11 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, control). The latest was on Aug 17, 2026.

  1. Aug 17, 2026ControlTo the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference. Filing
  2. Aug 10, 2026LeadershipAs previously disclosed in a current report on Form 8-K filed on June 11, 2026, Greg Tourangeau, Vice President, Finance and principal accounting officer of Fulcrum Therapeutics, Inc., or Fulcrum, mutually agreed with Fulcrum that Mr. Tourangeau will depart from his position at Fulcrum on a date to… Filing
  3. Jun 25, 2026VoteReported shareholder vote results. Filing
  4. Jun 11, 2026LeadershipAs previously disclosed, on May 31, 2026, the board of directors, or Board, of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following the discontinuation of development of pociredir for the treatment… Filing
  5. Jun 4, 2026AnnouncementAs previously disclosed, Fulcrum has initiated a comprehensive review of strategic alternatives intended to maximize stockholder value. Filing
  6. Jun 1, 2026AnnouncementFulcrum Therapeutics, Inc., or the Company, announced the discontinuation of its pociredir program for the treatment of sickle cell disease, or SCD, and the initiation of a comprehensive review of strategic alternatives intended to maximize stockholder value. Filing
  7. Apr 27, 2026LeadershipThe board of directors, or the Board, of Fulcrum, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Josh Lehrer as a member of the Board, with immediate effect. Filing
  8. Feb 24, 2026ResultsReleased financial results. Filing
  9. Jan 12, 2026ResultsReleased financial results. Filing
  10. Dec 11, 2025AgreementFulcrum Therapeutics, Inc., or Fulcrum, entered into an underwriting agreement, or the Underwriting Agreement, with J.P. Morgan Securities LLC, Leerink Partners LLC, and Cantor Fitzgerald & Co., as the representatives of the several underwriters, or the Underwriters, relating to an underwritten… Filing
  11. Dec 8, 2025AnnouncementFulcrum published a presentation announcing initial results of the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in SCD in connection with a presentation at the 67th American Society of Hematology Annual Meeting. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Fulcrum Therapeutics financials

Famous investors that hold FULC

4 of the 50 well-known investors we track reported holding FULC in their latest 13F filing. The largest position is Jim Simons's, worth $8.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 20262.22M$8.2M0.0%+35%
Steve Cohen · Point72 Asset ManagementQ3 2026917,801$3.4M0.0%+41%
Ken Griffin · Citadel AdvisorsQ3 2026516,185$1.9M0.0%-81%
Israel Englander · Millennium ManagementQ3 202642,930$159K0.0%-97%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 12 filings named FULC in the last 120 days.

FiledHolderFormStake
Nov 16, 2026ADAR1 Capital Management, LLC13G8.7%
Nov 16, 2026ADAR1 Capital Management, LLC13G8.7%
Nov 16, 2026EcoR1 Capital, LLC13G/A8.9%
Nov 16, 2026EcoR1 Capital, LLC13G/A8.9%
Nov 13, 2026Montanova Capital, LLC13G/A0.0%
Nov 13, 2026Nantahala Capital Management, LLC13G/A8.6%
Nov 13, 2026Montanova Capital, LLC13G/A0.0%
Nov 13, 2026Nantahala Capital Management, LLC13G/A8.6%
Oct 28, 2026BANK OF AMERICA CORP /DE/13G/A1.5%
Oct 28, 2026BANK OF AMERICA CORP /DE/13G/A1.5%
Oct 27, 2026BlackRock Portfolio Management LLC13G/A8.1%
Oct 27, 2026BlackRock Portfolio Management LLC13G/A8.1%

Questions about Fulcrum Therapeutics, Inc. (FULC) stock

Who owns the most FULC stock?

The largest reported owner of Fulcrum Therapeutics, Inc. (FULC) is Nantahala Capital Management, LLC, with 16.4% of the company. In total, 155 funds and institutions reported holding FULC at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are FULC insiders buying or selling?

In the last 12 months, FULC insiders reported 6 open-market purchases worth $1.5M and 9 sales worth $59.2M. The latest trade was on Jul 17, 2026. See every trade.

What is the short interest in FULC?

As of Oct 30, 2026, 6.44M FULC shares were sold short, 8.4% of the shares outstanding, down 4.7% from the report before. At the average daily volume of 1.34M shares, buying them all back would take about 4.8 trading days (days to cover). See the history.

Which famous investors hold FULC?

4 of the 50 well-known investors we track reported FULC in their latest 13F filing, including Jim Simons, Steve Cohen, Ken Griffin. The largest position is worth $8.2M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.